Cargando…

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations

Emerging data from global markets outside the United States, where many generic iron sucrose formulations are available, have revealed that non‐US generic intravenous (i.v.) iron formulations may have iron release profiles that differ from the reference listed drug (RLD). The first generic i.v. iron...

Descripción completa

Detalles Bibliográficos
Autores principales: Pai, AB, Meyer, DE, Bales, BC, Cotero, VE, Pai, MP, Zheng, N, Jiang, W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421824/
https://www.ncbi.nlm.nih.gov/pubmed/28160427
http://dx.doi.org/10.1111/cts.12443
_version_ 1783234656869548032
author Pai, AB
Meyer, DE
Bales, BC
Cotero, VE
Pai, MP
Zheng, N
Jiang, W
author_facet Pai, AB
Meyer, DE
Bales, BC
Cotero, VE
Pai, MP
Zheng, N
Jiang, W
author_sort Pai, AB
collection PubMed
description Emerging data from global markets outside the United States, where many generic iron sucrose formulations are available, have revealed that non‐US generic intravenous (i.v.) iron formulations may have iron release profiles that differ from the reference listed drug (RLD). The first generic i.v. iron approved in the United States was sodium ferric gluconate complex in 2011. We evaluated chelatable and redox labile iron assay methods to measure the amount of labile iron released from i.v. iron formulations in biorelevant matrices in vitro. The majority of published labile iron assays evaluated were not suitable for use in vitro due to overwhelming interference by the presence of the i.v. iron products. However, an optimized high‐performance liquid chromatography (HPLC)‐based method performed well for use in vitro labile iron detection in a biorelevant matrix. Application of this method may enhance bioequivalence evaluation of generic i.v. iron formulations in the future.
format Online
Article
Text
id pubmed-5421824
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54218242017-05-23 Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations Pai, AB Meyer, DE Bales, BC Cotero, VE Pai, MP Zheng, N Jiang, W Clin Transl Sci Research Emerging data from global markets outside the United States, where many generic iron sucrose formulations are available, have revealed that non‐US generic intravenous (i.v.) iron formulations may have iron release profiles that differ from the reference listed drug (RLD). The first generic i.v. iron approved in the United States was sodium ferric gluconate complex in 2011. We evaluated chelatable and redox labile iron assay methods to measure the amount of labile iron released from i.v. iron formulations in biorelevant matrices in vitro. The majority of published labile iron assays evaluated were not suitable for use in vitro due to overwhelming interference by the presence of the i.v. iron products. However, an optimized high‐performance liquid chromatography (HPLC)‐based method performed well for use in vitro labile iron detection in a biorelevant matrix. Application of this method may enhance bioequivalence evaluation of generic i.v. iron formulations in the future. John Wiley and Sons Inc. 2017-02-03 2017-05 /pmc/articles/PMC5421824/ /pubmed/28160427 http://dx.doi.org/10.1111/cts.12443 Text en © 2017 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research
Pai, AB
Meyer, DE
Bales, BC
Cotero, VE
Pai, MP
Zheng, N
Jiang, W
Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
title Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
title_full Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
title_fullStr Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
title_full_unstemmed Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
title_short Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
title_sort performance of redox active and chelatable iron assays to determine labile iron release from intravenous iron formulations
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421824/
https://www.ncbi.nlm.nih.gov/pubmed/28160427
http://dx.doi.org/10.1111/cts.12443
work_keys_str_mv AT paiab performanceofredoxactiveandchelatableironassaystodeterminelabileironreleasefromintravenousironformulations
AT meyerde performanceofredoxactiveandchelatableironassaystodeterminelabileironreleasefromintravenousironformulations
AT balesbc performanceofredoxactiveandchelatableironassaystodeterminelabileironreleasefromintravenousironformulations
AT coterove performanceofredoxactiveandchelatableironassaystodeterminelabileironreleasefromintravenousironformulations
AT paimp performanceofredoxactiveandchelatableironassaystodeterminelabileironreleasefromintravenousironformulations
AT zhengn performanceofredoxactiveandchelatableironassaystodeterminelabileironreleasefromintravenousironformulations
AT jiangw performanceofredoxactiveandchelatableironassaystodeterminelabileironreleasefromintravenousironformulations